Primary Series Hospitalization/Severe Disease mRNA ■ non-mRNA ■ Multiple Study Country Design VE (95% CI) Study End Date in 2021 С Bar-On et al., 2021 0.95 (0.92, 0.97) Israel Barda et al., 2021 MC 0.93 (0.88, 0.97) Israel ---- С Muhsen et al., 2022 0.93 (0.85, 0.97) Israel Sharma et al., 2021 USA MC 0.45 (0.27, 0.58) С 0.69 (0.56, 0.78) Mattiuzzi and Lippi, 2022 Italy С McConeghy et al., 2022 (S1) USA 0.82 (0.56, 0.94) USA С McConeghy et al., 2022 (S2) 0.46 (-0.16, 0.79)USA MC 0.81 (0.80, 0.82) Mehta et al., 2022 USA С Tartof et al., 2022 0.70 (0.48, 0.83) MC Butt et al, 2022 USA 0.52 (0.46, 0.57) UK Hulme et al., 2022 MC 0.80 (0.78, 0.82) Study End Date in 2022 Andersson et al., 2022 Finland MC 0.96 (0.88, 1.00) MC 0.88 (0.71, 1.00) Andersson et al., 2022 Norway 0.90 (0.80, 1.00) Andersson et al., 2022 Sweden MC Sweden MC 0.88 (0.81, 0.95) Andersson et al., 2022 USA \vdash loannou et al., 2022 MC 0.53 (0.48, 0.58) Ng et al., 2022 Singapore С 0.70 (0.49, 0.82) Kislaya et al., 2022 (60-79yo) Portugal С 0.21 (0.02, 0.36) С Kislaya et al., 2022 (80+yo) Portugal 0.16 (0.01, 0.28) Ridgway et al., 2022 USA **MCC** \vdash 0.59 (0.54, 0.63) Desai et al., 2022 USA MC 0.44 (0.02, 0.68) 0.80 (0.56, 0.91) Chemaitelly et al., 2022 Qatar MC -0.250.25 0 0.5 0.75 1 Vaccine Effectiveness (VE)

Mortality

